A Multicentre Phase III/IV Study, of the Effects of Risedronate Sodium (ACTONEL, 35mg/Week, Oral) on Bone, in Postmenopausal Women, With Hormone-receptor-positive Early Breast Cancer, Treated With Anastrozole (ARIMIDEX, 1mg/Day Oral) With Risk of Fragility Fracture (High-risk Fragility Fracture-open-label, Non-comparative Stratum; Moderate-risk of Fragility Fracture-randomised, Double-blind Stratum; Low-risk of Fragility Fracture - Open-label, Non-comparative Stratum)Abbreviated.

Trial Profile

A Multicentre Phase III/IV Study, of the Effects of Risedronate Sodium (ACTONEL, 35mg/Week, Oral) on Bone, in Postmenopausal Women, With Hormone-receptor-positive Early Breast Cancer, Treated With Anastrozole (ARIMIDEX, 1mg/Day Oral) With Risk of Fragility Fracture (High-risk Fragility Fracture-open-label, Non-comparative Stratum; Moderate-risk of Fragility Fracture-randomised, Double-blind Stratum; Low-risk of Fragility Fracture - Open-label, Non-comparative Stratum)Abbreviated.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2012

At a glance

  • Drugs Risedronic acid (Primary) ; Anastrozole
  • Indications Early breast cancer; Osteoporosis; Postmenopausal osteoporosis
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms SABRE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Jan 2010 Results were published in the Journal of Clinical Oncology.
    • 27 Feb 2009 New source identified and integrated (M.D. Anderson Cancer Center registry record).
    • 17 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top